Market Access AbbVie’s migraine drug cleared for migraine attacks on NHS PharmaphorumAbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.NeuroscienceRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) Pharmaphorum AbbVie’s Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Aditxt and Ignite announce merger plans with strategic partnerNext: Bayer’s asundexian starts EU review for ischaemic stroke Related Stories Market Access pharminent June 12, 2026 Market Access Aquipta recommended by NICE for acute migraine treatment pharminent June 10, 2026 Market Access Medicare Advantage in 2026: Enrollment Update and Key Trends pharminent June 5, 2026
